Lonza Cologne GmbH

About Lonza Cologne GmbH

Lonza Cologne GmbH offers products for various everyday uses, such as disinfectants and detergents in hospitals or pool and spa areas, in pesticides against snails (metaldehyde), in sports and energy drinks (vitamin B3, L-Carnitine) or in body lotions as emulsifying agents.

At the BioCampus Cologne, Lonza’s Bioscience Solutions staff develops and commercializes non-viral gene transfer products for primary cells and hard-to-transfect cell lines. Primary cells more accurately reflect the condition and behavior of cells within an organism when compared to commonly used laboratory cell lines. Therefore, they are important model systems for both basic and clinical research. With Lonza’s Nucleofector™ Technology, the functionality of different genes can be analyzed in biologically relevant cell types. These results help identify possible new pharmaceuticals and therapies, for example to fight cancer or cardiovascular diseases.

In addition, Cologne is the German distribution center for further Lonza businesses. Thus, customers are served in different areas, such as endotoxin detection, water treatment, personal care, health and hygiene, industrial conservation, material preservation, wood treatment, nutrition and agriculture.

About Lonza

Lonza is one of the world’s leading and most trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza’s stock is publicly traded on the Swiss and the Singapore stock exchanges.